Mirum Advances Brelovitug in Phase 3 Hepatitis Delta Trial
Foster City, California, U.S., September 28, 2026 Mirum Pharmaceuticals has reported a significant clinical-development milestone for brelovitug, an investigational...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Foster City, California, U.S., September 28, 2026 Mirum Pharmaceuticals has reported a significant clinical-development milestone for brelovitug, an investigational...
Indianapolis, Indiana, U.S., September 24, 2026 Eli Lilly and Company has reached a major milestone in diabetes care following...
Indianapolis, Indiana, U.S., September 24, 2026 Eli Lilly and Company has received U.S. Food and Drug Administration (FDA) approval...
Plainsboro, New Jersey, August,11, 2026 Novo Nordisk has announced the nationwide U.S. launch of Awiqli® (insulin icodec-abae) injection 700...
BRIDGEWATER, N.J., and BENGALURU, India – October 16, 2025: Biocon Biologics Ltd., a global leader in biosimilars, has expanded...
